Showing results for 
Search instead for 
Did you mean: 

BLOG: Focal Therapy for Localised Prostate Cancer

Community Manager
Community Manager
0 0 387

Focal therapy for localised prostate cancer

The main goal of focal therapy is the targeted focal destruction of cancer tissue with the preservation of surrounding healthy prostate tissue. There have been conflicting opinions on the definition, but it seems the consensus is “ablation of the dominant or index lesion”1. The principle of targeted therapy has been applied to other cancers such as breast, liver, brain, and thyroid. It represents the middle ground between active surveillance and treatments such as radical prostatectomy and radiation therapy. The reported benefit of focal therapy is the preservation of sexual function and urinary continence. This is because the energy destroying the cancer is focused only on the affected area within the prostate, sparing any injury to nerves running on the outside of the prostate that supply’s the external urinary sphincter or the erectile mechanism of the penis.

Over 90% of patients present with cancer in multiple areas within the prostate (multifocal) and only 20–40% have cancer in one area. Despite the multifocal nature of prostate cancer, many cancerous prostates have “a single substantial lesion” (index lesion). It has been proposed that the characteristics of the index lesion predict the behaviour of disease in the rest of the prostate and it’s metastatic potential. So by targeting the index lesion in men with low and intermediate-volume prostate cancer it will provide satisfactory oncological outcomes. Patients should have a life expectancy (> 5 years); a performance status of 0/1 and a Gleeson score < 8. High grade prostate cancer has to be excluded with a template guided prostate biopsy and the prostate is mapped with an MRI. For the procedure to be successful there should be at least a 3mm margin around the index lesion1.

Several energy modalities exist to target the cancer including irreversible electroporation, laser ablation, high intensity focused ultrasound (HIFU), cryotherapy, and photodynamic therapy. The rest of this blog will discuss three modalities currently available in Australia: Irreversible electroporation, HIFU, and laser ablation.

Irreversible electroporation

This treatment is delivered using the Nanoknife system with a low-energy direct current to the focal region. The lesion is delineated by needles which are positioned with ultrasound guidance. Electropulses cause complete ablation with no thermal damage. In a cohort study of 112 patients, from St Vincent’s Hospital found an overall survival rate of 100%, metastasis-free survival of 99%, failure free survival of 97% at three years2. With regard to incontinence, 98% remained pad free and 76% had no change in erectile function. Twelve patients had to have a repeat treatment.


Uses ultrasonic waves to initiate cellular damage. 'High-intensity' refers to the power of these sound waves. The ultrasound probe is placed in the rectum allowing real-time visualization of prostatic tissue and also delivering energy to destroy the desired target area. The procedure can be technically challenging if the prostate has numerous large calcifications. Isolating the focal area is complex and can result in retreatment rates of up to 34%, more researched is required here. A Professor from the Alfred Hospital in Melbourne prefers a whole gland approach as reported in his study of 70 men with a 8 year follow up. Failure-free survival was 71.2% at 7 years and 7.1% of men developed metastases with median metastasis-free survival of 75.4 months. Whole gland HIFU preserved urinary continence and demonstrated erectile function approximate to a nerve-sparing radical prostatectomy.

Laser ablation

A laser probe is introduced through the perineum into the prostate under MRI or ultrasound guidance, facilitated using a grid. Once in position, ablation is monitored using the aforementioned imaging modalities, which indicate whether adequate temperatures have been achieved to destroy cancerous tissue. A Professor from the Nepean Hospital in his series of 49 patients found a significant PSA drop and MRI improvement at 18 months4. There was no impact on urinary and sexual function. Persistent cancer was found in 10 patients.

Locally access to these therapies is either through a clinical trial or at specific private institutions and may not always be supported by private health funds.

Comparison between treatment modalities is troublesome given the large variation in treatment administration and follow-up protocols in various studies. In general patient requires follow up with PSA monitoring and regular MRIs. Any rise in PSA or suspicious lesion on MRI would warrant a repeat prostate biopsy. At present there is limited consensus on the definition of treatment failure and success.

Many of the trials require longer follow up outcomes. As experience in focal therapy broadens however, extended periods of follow-up data will soon become available which will be useful to create standardised guidelines for many of these treatment approaches in this select patient population.



Perera, M., Krishnananthan, N., Lindner, U. Lawrentschuk N. An update on focal therapy for prostate cancer. Nat Rev Urol 13, 641–653 (2016).

Blazeyski A, Scheltema MJ, Yuen B, Masand N, Nguyen TV, Delprado W, Shnier R, Haynes A, Cusick T, Thompson J, Stricker P. Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: A biopsy-monitored prospective cohort. European Urology Oncology 2020; 3 (3)283-290.

Royce PL, 0oi JJY, Sothilingam S, Yao HH. Survival and quality of life outcomes of high-intensity focused ultrasound treatment of localized prostate cancer. Prostate Int. 2020 Jun;8(2):85-90.

Al-Hakeem Y, Raz O, Gacs Z, Maclean F, Varol C. Magnetic resonance image-guided focal laser ablation in clinically localized prostate cancer: safety and efficacy. ANZ J Surg 2019; 89(12) 1610-14.






 About the Author

Kalli Spencer

MBBCh, FC Urol (SA), MMed (Urol), Dip.Couns (AIPC)

Kalli is an internationally renowned Urological Surgeon, specialising in oncology and robotic surgery. He trained and worked in South Africa, before relocating to Australia where he has worked at Macquarie University Hospital and Westmead Hospital. His passion for what he does extends beyond the operating room, through public health advocacy, education and community awareness of men’s health, cancer and sexuality.

Kalli has been involved with the Prostate Cancer Foundation of Australia for many years, advocating for improved cancer care and facilitating community prostate cancer support groups.


Please note that the options discussed in this blog require longer follow-up outcomes and further research into effectiveness. These treatments are not available in all treatment centers.
Please phone our Telenurse team to discuss options that are available to you and your circumstances. PCFA supports innovation and research into treatment options and survivorship and welcomes further research in these areas.

If you would like to discuss your individual treatment options further or require more information and resources about your prostate cancer journey, reach out to us, as help is available

Phone PCFA on 1800 22 00 99


Help is Available

Prostate Cancer Specialist Telenursing Service:

If your life has been impacted by prostate cancer, our Specialist Telenursing Service is available to help. If you would like to reach out to the PCFA Prostate Cancer Specialist Telenurse Service for any questions you have about your prostate cancer experience, please phone 1800 22 00 99 Monday - Friday 9am - 5pm, Wednesday 10am-8pm (AEST).


Prostate Cancer Support Groups:

PCFA is proud to have a national network of affiliated support groups in each state and territory of Australia consisting of men and women who have a passion for assisting others who encounter prostate cancer. This network is made up of over 170 affiliated groups who meet locally to provide one-to-one support, giving a vision of life and hope after treatment. Call us on 1800 22 00 99 to find your local group.


MatesCONNECT Telephone-based peer support:

MatesCONNECT is a telephone-based peer support program for men affected by prostate cancer. If you’ve recently been diagnosed with prostate cancer, our MatesCONNECT service can connect you to a trained volunteer who understands what you’re going through. All of our volunteers have been through prostate cancer. Simply call us on 1800 22 00 99 to be connected with a volunteer.


Newly diagnosed? or need to find more information -Access the PCFA resources here!

House Rules

To help keep this community a welcoming, supportive and caring place we have put together a small list of dos and don'ts for you to think about when posting on our forum, research blog or video gallery. For further information please see our  terms and conditions.

Adhere to PCFA’s five core values of Integrity, Optimism, Compassion, Respect and Commitment.

Our online forum is for you to share experiences with others and does not contain specific medical, counselling or legal advice.  If you require professional advice specific to your individual circumstances we encourage you to see a medical professional, legal professional or counsellor.

No commercial or promotional activity. While members may share information about resources they have found helpful, the PCFA Online Community forum should not be used for the promotion of goods and services. This includes commercial entities passing themselves off as individuals and people who frequently post links to external health professionals or other services.

Be kind to each other - many people using the community are going through a difficult time. A few kind words can go a long way. Please welcome new posters – it can be very nerve-wracking to post on the forum for the first time.

If you or someone you know is suffering from mental health issues, such as depression or anxiety, we encourage you to seek assistance and contact Beyond Blue Tel:1300 224 636 or Lifeline Tel:13 11 14

Speak your mind freely, but please be sensitive to the feelings and experiences of others - you might not always agree, but you can agree to disagree in a peaceful manner.

Don't use offensive language -if a user is found to be using offensive language during their conversations the moderators reserve the right to edit the thread, without warning.

Don't use all capital letters in your posts - it's considered ‘shouting' online and it makes posts difficult to read.

Give each other the benefit of the doubt - please remember that it is all too easy for the tone and meaning of posts to be misinterpreted. Think carefully before replying to a discussion. it It is important to remember that things written rather than said can feel much stronger, so please bear this in mind when reading other people's messages.

Please respect the moderators - their job is to keep the forum safe and constructive so that everybody gets to have his or her fair say.

Stay on topic - try to focus on the original topic. In particular, don't change subject in the middle of an existing thread - just start a new thread.

Read what's already on the forum before posting - you may be repeating what others have already said or asked.

We want PCFA's Online Community to be a secure and helpful environment for all of the community. So please remember that by using PCFA's Online Community you are agreeing to follow our terms and conditions.